MERUS BV

NASDAQ: MRUS (Merus N.V.)

最近更新时间: 2天之前, 2:34AM

96.93

0.30 (0.31%)

前收盘价格 96.63
收盘价格 96.80
成交量 706,989
平均成交量 (3个月) 2,473,476
市值 7,351,866,880
价格/销量 (P/S) 121.02
股市价格/股市净资产 (P/B) 9.43
52周波幅
33.19 (-65%) — 96.94 (0%)
利润日期 12 Nov 2025
营业利益率 (TTM) -285.94%
稀释每股收益 (EPS TTM) -4.16
季度收入增长率 (YOY) 235.80%
总债务/股东权益 (D/E MRQ) 1.65%
流动比率 (MRQ) 5.86
营业现金流 (OCF TTM) -237.91 M
杠杆自由现金流 (LFCF TTM) -112.40 M
资产报酬率 (ROA TTM) -30.61%
股东权益报酬率 (ROE TTM) -58.66%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Merus N.V. 混合的 看涨

AIStockmoo 评分

-0.1
分析师共识 0.5
内部交易活动 NA
价格波动 -0.5
技术平均移动指标 -2.5
技术振荡指标 2.0
平均 -0.13

相关股票

股票 市值 DY P/E(TTM) P/B
MRUS 7 B - - 9.43
ROIV 15 B - - 3.23
VRTX 116 B - 31.86 6.62
ABVX 10 B - - 8.74
ZLAB 2 B - - 2.66
CORT 9 B - 101.14 14.33

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Growth
内部持股比例 2.33%
机构持股比例 99.34%
52周波幅
33.19 (-65%) — 96.94 (0%)
目标价格波幅
96.00 (-0%) — 97.00 (0%)
97.00 (Leerink Partners, 0.07%) 保留
97.00 (Canaccord Genuity, 0.07%) 保留
97.00 (Wells Fargo, 0.07%) 保留
97.00 (UBS, 0.07%) 保留
97.00 (LifeSci Capital, 0.07%) 保留
97.00 (Barclays, 0.07%) 保留
97.00 (HC Wainwright & Co., 0.07%) 保留
97.00 (Guggenheim, 0.07%) 保留
97.00 (Citigroup, 0.07%) 保留
97.00 (Truist Securities, 0.07%) 保留
97.00 (0.07%)
96.00 (Needham, -0.96%) 保留
平均值 96.91 (-0.02%)
总计 11 保留
平均价格@调整类型 94.03
公司 日期 目标价格 调整类型 价格@调整类型
Leerink Partners 06 Oct 2025 97.00 (0.07%) 保留 94.27
Barclays 30 Sep 2025 97.00 (0.07%) 保留 94.15
17 Sep 2025 112.00 (15.55%) 购买 68.18
Canaccord Genuity 30 Sep 2025 97.00 (0.07%) 保留 94.15
Guggenheim 30 Sep 2025 97.00 (0.07%) 保留 94.15
HC Wainwright & Co. 30 Sep 2025 97.00 (0.07%) 保留 94.15
LifeSci Capital 30 Sep 2025 97.00 (0.07%) 保留 94.15
UBS 30 Sep 2025 97.00 (0.07%) 保留 94.15
Wells Fargo 30 Sep 2025 97.00 (0.07%) 保留 94.15
29 Sep 2025 97.00 (0.07%) 保留 93.67
Citigroup 29 Sep 2025 97.00 (0.07%) 保留 93.67
Needham 29 Sep 2025 96.00 (-0.96%) 保留 93.67
Truist Securities 29 Sep 2025 97.00 (0.07%) 保留 93.67
显示更多

该时间范围内无数据。

日期 类型 细节
12 Dec 2025 公告 Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
17 Nov 2025 公告 Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
24 Oct 2025 公告 Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
24 Oct 2025 公告 Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
14 Oct 2025 公告 Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
14 Oct 2025 公告 Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13 Oct 2025 公告 Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13 Oct 2025 公告 Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
29 Sep 2025 公告 Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票